RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development

Core Insights - ADC Therapeutics (NYSE:ADCT) is highlighted as a promising investment opportunity, particularly in the context of its lymphoma treatment developments [1][2] - Recent positive interim Phase Ib data from the LOTIS-7 trial has led to reaffirmed buy ratings from analysts, with price targets set at $10.00 by Guggenheim and $5.00 by RBC Capital [1][2] Trial Results - The LOTIS-7 trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% among 49 efficacy-evaluable patients, indicating strong efficacy for ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma [3] - The trial results support the potential of ZYNLONTA and glofitamab as leading bispecific antibody-based combinations for patients with 2L+ DLBCL [3] Regulatory Approvals - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma, enhancing its market position [5][6] Company Overview - ADC Therapeutics is a commercial-stage biotech company focused on developing targeted cancer therapies using Antibody-Drug Conjugates (ADCs) and proprietary Pyrrolobenzodiazepine (PBD) technology [6]